<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.1//EN" "http://www.w3.org/TR/xhtml11/DTD/xhtml11.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
<title>Fleeting_SfN2025_Bibliography</title>
</head>
<body>

<div style="text-align: center; margin-bottom: 2em;">
  <p style="font-size: 1.5em; font-weight: bold; margin-bottom: 0.5em; margin-top: 0;">
    Association of Pavlovian Bias with Apathy and Impulsivity in Patients Receiving Deep Brain Stimulation for Parkinson’s Disease
  </p>
  <p style="font-size: 1.1em; margin-bottom: 0.5em;">
    <b>Chance Fleeting</b><sup>1*&dagger;</sup>, <b>Robert S. Eisinger</b><sup>2&dagger;</sup>, Maxwell Woolridge<sup>3</sup>, and Aysegul Gunduz<sup>1</sup>
  </p>
  <p style="font-size: 0.9em; font-style: italic; margin-top: 0; margin-bottom: 1em;">
    <sup>1</sup>J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA  
    <sup>2</sup>Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA  
    <sup>3</sup>College of Medicine, University of Florida, Gainesville, FL, USA  
    <sup>&dagger;</sup>Shared First Authorship.
  </p>
  <p style="font-size: 1em; margin-top: 0;">
    Presented at the <i>Society for Neuroscience Annual meeting (Neuroscience 2025)</i>, November 15 – 19<sup>th</sup>, 2025, San Diego, CA.
  </p>
</div>

<hr style="margin-top: 2em;"/>

<div style="font-weight: bold; font-size: 1.2em; margin-bottom: 0.3em;"><b>References</b></div>

<div class="csl-bib-body" style="line-height: 1.35;">
  <div class="csl-entry" style="margin-bottom: 0.675em;">1.	L. Peña-Zelayeta <i>et al.</i>, “Redefining Non-Motor Symptoms in Parkinson’s Disease,” <i>J. Pers. Med.</i>, vol. 15, no. 5, p. 172, 2025, doi: <a href="https://doi.org/10.3390/jpm15050172">10.3390/jpm15050172</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">2.	I. Rektorova, “Current treatment of behavioral and cognitive symptoms of Parkinson’s disease,” <i>Parkinsonism Relat. Disord.</i>, vol. 59, pp. 65–73, 2019, doi: <a href="https://doi.org/10.1016/j.parkreldis.2019.02.042">10.1016/j.parkreldis.2019.02.042</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">3.	R. S. Eisinger <i>et al.</i>, “Pavlovian bias in Parkinson’s disease: an objective marker of impulsivity that modulates with deep brain stimulation,” <i>Sci. Rep.</i>, vol. 10, p. 13448, 2020, doi: <a href="https://doi.org/10.1038/s41598-020-69760-y">10.1038/s41598-020-69760-y</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">4.	S. Hirano, “Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson’s disease,” <i>Mol. Med.</i>, vol. 27, no. 1, p. 40, 2021, doi: <a href="https://doi.org/10.1186/s10020-021-00301-7">10.1186/s10020-021-00301-7</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">5.	H. Sparks <i>et al.</i>, “Impulsivity Relates to Relative Preservation of Mesolimbic Connectivity in Patients with Parkinson Disease,” <i>NeuroImage: Clin.</i>, vol. 27, p. 102259, 2020, doi: <a href="https://doi.org/10.1016/j.nicl.2020.102259">10.1016/j.nicl.2020.102259</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">6.	F. Javoy-Agid and Y. Agid, “Is the mesocortical dopaminergic system involved in Parkinson disease?” <i>Neurology</i>, vol. 30, no. 12, pp. 1326–1330, 1980, doi: <a href="https://doi.org/10.1212/wnl.30.12.1326">10.1212/wnl.30.12.1326</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">7.	M. Guitart-Masip <i>et al.</i>, “Differential, but not opponent, effects of L-DOPA and citalopram on action learning with reward and punishment,” <i>Psychopharmacology (Berl.)</i>, vol. 231, no. 5, pp. 955–966, 2014, doi: <a href="https://doi.org/10.1007/s00213-013-3313-4">10.1007/s00213-013-3313-4</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">8.	J.-L. Houeto <i>et al.</i>, “Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson’s Disease?” <i>Front. Psychiatry</i>, vol. 7, 2016, doi: <a href="https://doi.org/10.3389/fpsyt.2016.00091">10.3389/fpsyt.2016.00091</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">9.	B. M. Scott <i>et al.</i>, “Co-Occurrence of Apathy and Impulse Control Disorders in Parkinson Disease: Variation across Multiple Measures,” <i>Arch. Clin. Neuropsychol.</i>, 2024, doi: <a href="https://doi.org/10.1093/arclin/acae036">10.1093/arclin/acae036</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">10.	G. Maggi <i>et al.</i>, “Anatomical correlates of apathy and impulsivity co-occurrence in early Parkinson’s disease,” <i>J. Neurol.</i>, vol. 271, no. 5, pp. 2798–2809, 2024, doi: <a href="https://doi.org/10.1007/s00415-024-12233-3">10.1007/s00415-024-12233-3</a>.</div>

  <div class="csl-entry" style="margin-bottom: 0.675em;">11.	H. Theis <i>et al.</i>, “Impulsive-compulsive behaviour in early Parkinson’s disease is determined by apathy and dopamine receptor D3 polymorphism,” <i>npj Parkinson’s Dis.</i>, vol. 9, p. 154, 2023, doi: <a href="https://doi.org/10.1038/s41531-023-00596-9">10.1038/s41531-023-00596-9</a>.</div>
</div>

<hr style="margin-top: 2em;"/>

<p style="text-align: left;">
<b><sup>*</sup>Contact:</b><br/>
Chance Fleeting<br/>
Email: <a href="mailto:cfleeting@ufl.edu">cfleeting@ufl.edu</a><br/>
ORCID: <a href="https://orcid.org/0000-0002-6271-4952">https://orcid.org/0000-0002-6271-4952</a>
</p>

</body>
</html>
